Spin-off Company Forms to Advance Potential Cancer Treatment
Post Date: April 30, 2020 | Publish Date:
Seed investor CincyTech has announced the formation of Kurome Therapeutics (“Kurome”), a spin-off company based on cancer research discoveries made at Cincinnati Children’s by Daniel Starczynowski, PhD, and colleagues.
Kurome is developing combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of chemotherapy drugs by adaptive resistance, having co-opted immune signaling pathways to survive.
Read more about this line of research:
NIH, Cincinnati Children’s Scientists Develop Potential Strategy Against Leukemia Drug Resistance
Overlooked Molecular Machine in Cell Nucleus May Hold Key to Treating Aggressive Leukemia
Science Translational Medicine: Overcoming adaptive therapy resistance in AML by targeting immune response pathways
